Literature DB >> 2934521

Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement.

A R Fritzberg, S Kasina, D Eshima, D L Johnson.   

Abstract

A new technetium-chelating agent based on a triamide monomercaptide tetradentate set of donor groups, mercaptoacetylglycylglycylglycine (MAG3), was synthesized and evaluated. Chelation with 99mTc resulted in a single radiochemical product as expected. Studies in mice of [99mTc]MAG3 indicated excretion rates faster than omicron-iodohippurate (OIH) both in normal and in probenecid treated animals. Specificity for renal excretion was essentially complete. Clearance studies in rats resulted in 2.84 ml/min/100 g for [99mTc]MAG3, 2.17 for OIH, and 1.29 for [125I]iothalamate. Extraction efficiencies were 85% for [99mTc]MAG3, 69% for OIH and 39% for [125I]iothalamate. Probenicid depressed the clearance both of [99mTc]MAG3 and OIH at 25 and 50 mg/kg/hr, but to a greater extent with [99mTc]MAG3. The greater effect is offset, however, by the larger fraction secreted by the renal tubular cells. The animal results suggest that [99mTc]MAG3 may be a useful alternative to [131I]OIH.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2934521

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  35 in total

1.  Comparison of technetium-99m MAG3 kit formulations in Europe and the USA.

Authors:  J C Hung
Journal:  Eur J Nucl Med       Date:  1992

2.  Preparation and Evaluation of (68)Ga-ECC as a PET Renal Imaging Agent.

Authors:  Alireza Mirzaei; Amir Reza Jalilian; Ayuob Aghanejad; Mohammad Mazidi; Hassan Yousefnia; Gholamali Shabani; Khosro Ardaneh; Parham Geramifar; Davood Beiki
Journal:  Nucl Med Mol Imaging       Date:  2015-02-24

3.  Performance evaluation of stationary and semi-stationary acquisition with a non-stationary small animal multi-pinhole SPECT system.

Authors:  Catharina Lange; Ivayla Apostolova; Mathias Lukas; Kai P Huang; Frank Hofheinz; Betina Gregor-Mamoudou; Winfried Brenner; Ralph Buchert
Journal:  Mol Imaging Biol       Date:  2013-11-09       Impact factor: 3.488

4.  What does protein binding of radiopharmaceuticals mean exactly?

Authors:  O Jeghers; A Piepsz; H R Ham
Journal:  Eur J Nucl Med       Date:  1990

5.  An investigation of factors that might influence the radiochemical purity and stability of 99mTc-MAG3.

Authors:  A M Millar; L M O'Brien
Journal:  Eur J Nucl Med       Date:  1990

6.  The SNMMI and EANM practice guideline for renal scintigraphy in adults.

Authors:  M Donald Blaufox; Diego De Palma; Andrew Taylor; Zsolt Szabo; Alain Prigent; Martin Samal; Yi Li; Andrea Santos; Giorgio Testanera; Mark Tulchinsky
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-30       Impact factor: 9.236

7.  99mTc-MAG3: dynamic studies in patients with renal disease.

Authors:  G H Schaap; T H Alferink; R B de Jong; P L Oe; J C Roos; A J Donker
Journal:  Eur J Nucl Med       Date:  1988

8.  A simple two-strip method to determine the radiochemical purity of technetium-99m mercaptoacetyltriglycine.

Authors:  F Chen; C Decristoforo; B Rohrbacher; G Riccabona
Journal:  Eur J Nucl Med       Date:  1993-04

9.  99mTc(CO)3(NTA) and 131I-OIH: comparable plasma clearances in patients with chronic kidney disease.

Authors:  Andrew T Taylor; Malgorzata Lipowska; Hui Cai
Journal:  J Nucl Med       Date:  2013-02-19       Impact factor: 10.057

10.  Technetium-99m mercaptoalbumin as a potential substitute or technetium-99m labelled red blood cells.

Authors:  K A Verbeke; H P Vanbilloen; M J De Roo; A M Verbruggen
Journal:  Eur J Nucl Med       Date:  1993-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.